A W Ford‐Hutchinson
United States Nuclear Regulatory Commission(US)
Publications by Year
Research Areas
Asthma and respiratory diseases, Inflammatory mediators and NSAID effects, Estrogen and related hormone effects, Eicosanoids and Hypertension Pharmacology, Immune Response and Inflammation
Most-Cited Works
- → Etoricoxib (MK-0663): Preclinical Profile and Comparison with Other Agents That Selectively Inhibit Cyclooxygenase-2(2001)457 cited
- → The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor(1999)427 cited
- → Rofecoxib [Vioxx, MK-0966; 4-(4′-Methylsulfonylphenyl)-3-phenyl-2-(5 H)-furanone]: A Potent and Orally Active Cyclooxygenase-2 Inhibitor. Pharmacological and Biochemical Profiles(1999)398 cited
- → L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2-dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor(1989)328 cited
- → Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX‐2 inhibitor(1997)326 cited
- → Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach.(1995)313 cited
- → Pharmacology of montelukast sodium (Singulair™), a potent and selective leukotriene D4receptor antagonist(1995)251 cited
- → Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation.(1992)172 cited
- → Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)-indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor(1992)113 cited
- → L-649,923, Sodium (βS*, γR*)-4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)-propylthio)-γ-hydroxy-β-methylbenzenebutanoate, a selective, orally active leukotriene receptor antagonist(1986)63 cited